A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Issue 6 (2nd June 2016)

Record Type:: Journal Article
Title:: A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Issue 6 (2nd June 2016)
Main Title:: A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191
Authors:: Hay, Annette E.
Murugesan, Alli
DiPasquale, Ashley M.
Kouroukis, Tom
Sandhu, Irwindeep
Kukreti, Vishal
Bahlis, Nizar J.
Lategan, Johan
Reece, Donna E.
Lyons, John F.
Sederias, Joana
Xu, Hao
Powers, Jean
Seymour, Lesley K.
Reiman, Tony
Abstract:
Is Part Of:: Leukemia & lymphoma. Volume 57:Issue 6(2016:Jun.)
Journal:: Leukemia & lymphoma
Issue:: Volume 57:Issue 6(2016:Jun.)
Issue Display:: Volume 57, Issue 6 (2016)
Year:: 2016
Volume:: 57
Issue:: 6
Issue Sort Value:: 2016-0057-0006-0000
Page Start:: 1463
Page End:: 1466
Publication Date:: 2016-06-02
Subjects:: Leukemia -- Periodicals
Lymphomas -- Periodicals
616.99419
Journal URLs:: http://informahealthcare.com ↗
DOI:: 10.3109/10428194.2015.1091927 ↗
Languages:: English
ISSNs:: 1042-8194
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 5185.251500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 2727.xml